D46.21 Refractory anemia with excess of blasts 1

Name of the Condition

• Refractory anemia with excess of blasts 1

Summary

Refractory anemia with excess of blasts 1 (RAEB-1) is a subtype of myelodysplastic syndrome (MDS) characterized by ineffective blood cell production in the bone marrow, leading to low blood cell counts (cytopenias) and abnormal cell development. The condition is termed "refractory" because it does not respond to standard treatments for anemia. RAEB-1 is distinguished by the presence of an increased number of immature blood cells (blasts) in the bone marrow and blood, and it carries a higher risk of progressing to acute myeloid leukemia (AML) compared to other MDS subtypes.

Causes

The exact cause of RAEB-1 is often unknown. It may involve genetic mutations that disrupt normal blood cell production. Other factors can include previous chemotherapy or radiation therapy, exposure to certain chemicals (e.g., benzene), and rarely, inherited bone marrow failure syndromes.

Risk Factors

• Age (most common in individuals over 60)
• Previous cancer treatment with chemotherapy or radiation
• Exposure to industrial chemicals like benzene
• Family history of MDS or other blood disorders
• Certain genetic conditions (e.g., Fanconi anemia)

Symptoms

• Fatigue or weakness
• Frequent infections
• Easy or unexplained bruising or bleeding
• Shortness of breath
• Pale skin
• Unexplained weight loss

Diagnosis

Diagnosis involves a complete blood count (CBC) to identify cytopenias, followed by a bone marrow biopsy to assess cell dysplasia and blast percentage. Cytogenetic analysis may be performed to detect chromosomal abnormalities, and additional tests may evaluate iron stores or rule out other conditions.

Treatment Options

Treatment depends on the patient’s age, overall health, and disease severity. Options may include supportive care (e.g., blood transfusions, growth factors), hypomethylating agents (e.g., azacitidine), and in some cases, stem cell transplantation. Clinical trials may be considered for eligible patients.

Prognosis and Follow-Up

RAEB-1 has a higher risk of progressing to AML compared to lower-risk MDS subtypes. Prognosis varies based on factors like blast count, cytogenetics, and patient age. Regular follow-up with blood counts and bone marrow evaluations is typically recommended to monitor disease progression.

Complications

• Progression to acute myeloid leukemia (AML)
• Severe anemia requiring frequent transfusions
• Increased risk of infections due to low white blood cell counts
• Bleeding complications from low platelet counts

Lifestyle & Prevention

• Avoid exposure to known toxins (e.g., benzene)
• Maintain a balanced diet to support overall health
• Practice good hygiene to reduce infection risk
• Follow up regularly with healthcare providers for monitoring

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, unexplained bruising or bleeding, frequent infections, or shortness of breath. These symptoms may indicate worsening cytopenias or disease progression.

Tips for Medical Coders

Document the blast percentage in the bone marrow (5%–9% for RAEB-1) and any associated cytogenetic findings. Ensure the diagnosis aligns with WHO criteria for MDS subtypes. Include details on prior treatments (e.g., chemotherapy) or exposure to environmental toxins if relevant to support coding accuracy.